Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.
BuchGebunden
215 Seiten
Englisch
Springererschienen am31.10.20171st ed. 2018
This book covers various aspects of a respiratory system disorder associated with prescribed drugs that do not yet have established treatment guidelines, and for which the only treatment is to discontinue taking the drug.mehr
Verfügbare Formate
BuchKartoniert, Paperback
EUR106,99
BuchGebunden
EUR106,99
E-BookPDF1 - PDF WatermarkE-Book
EUR96,29

Produkt

KlappentextThis book covers various aspects of a respiratory system disorder associated with prescribed drugs that do not yet have established treatment guidelines, and for which the only treatment is to discontinue taking the drug.
Zusammenfassung
Introduces representative drugs causing the disorder such as antineoplastic drugs, biological products, and molecular target drugs

Will not only benefit respiratory physicians but all medical clinicians who prescribe drugs, nurses, pharmacists and pharmaceutical scientists

Fosters a deeper understanding of the disorder, highlights the current challenges and paves the way for future clinical research
Details
ISBN/GTIN978-981-10-4465-6
ProduktartBuch
EinbandartGebunden
Verlag
Erscheinungsjahr2017
Erscheinungsdatum31.10.2017
Auflage1st ed. 2018
ReiheRespiratory Disease Series: Diagnostic Tools and Disease Managements
Seiten215 Seiten
SpracheEnglisch
Gewicht464 g
IllustrationenVIII, 215 p. 53 illus., 15 illus. in color.
Artikel-Nr.42527266
Rubriken
GenreMedizin

Inhalt/Kritik

Inhaltsverzeichnis
Part IãDefinition, Pathogenesis, and Epidemiology.- 1. Definition, Pathogenesis and Epidemiology: What is DLI?.- 2. Epidemiology and Risk Factors of Drug-Induced Lung Disease: What are the prevalence and risk factors of DLI?.- 3. Clinical Characteristics of DLI: What are the clinical features of DLI?.- Part IIãDiagnosis.- 4. Diagnostic Approach for DLI: How is DLI diagnosed?.- 5. Blood tests for the diagnosis and/or management of DLI: What are the clinical significances of KL-6, SP-A, SP-D and DLST in DLI?.- 6. Imaging features of drug-induced interstitial lung disease: How HRCT of DLI is interpreted?.- 7. Pathology of DLI: What is the pathological significance of DLI?.- 8. Differential Diagnosis of DLI: What are the differential diagnoses of DLI?.- Part IIãTreatment.- 9. Therapeutic Strategies for DLI: How should DLI be treated?.- Part IVãDrugs Causing DLI.- 10. DLI induced by non-molecular target antineoplastic drugs: What are the characteristics of DLI in non-molecular target antineoplastic drugs?.- 11. DLI induced by Molecular Target Antineoplastic Drug: What are the characteristics of DLI in molecular target antineo-plastic drugs?.- 12. DLI caused by disease-modifying antirheumatic drugs: What are the characteristics of DLI by disease-modifying antirheumatic drugs?.- 13. DLI Induced by Herbal Medicine: What are the characteristics of DLI due to herbal medicines?.- 14. DLI induced by Antiarrhythmic Drug and Antimicrobial Drug: What are the characteristics of DLI in antiarrhythmic drugs and antimicrobial drugs?.mehr

Autor

Editors

Masayuki Hanaoka
First Department of Medicine
Shinshu University School of Medicine
Matsumoto, Japan

Hiroyuki Nakamura
Department of Respiratory Medicine
Tokyo Medical University Ibaraki Medical Center
Ibaraki, Japan

Kazutetsu Aoshiba
Department of Respiratory Medicine
Tokyo Medical University Ibaraki Medical Center
Ibaraki, Japan
Weitere Artikel von
Herausgegeben:Hanaoka, Masayuki